jetcityimage
A new study found that patients taking Eli Lilly’s (NYSE:LLY) Mounjaro lost significantly more weight than those taking Novo Nordisk’s (NVO) Ozempic.
The study, which analyzed the electronic health records of roughly 41,000 obese or overweight patients who took the drugs, found that the mean loss in body weight at three months of use was 5.9% for Mounjaro users versus 3.6% for Ozempic users.
At six months of use, the mean loss was 10.1% for Mounjaro users compared with 5.8% for Ozempic users. The mean body weight loss at 12 months was 15.3% for Mounjaro users versus 8.3% for those using Ozempic. The risk of gastrointestinal adverse events was similar for both drugs.
The study was published Monday on the JAMA Internal Medicine website.
Mounjaro’s active ingredient is tirzepatide, while Ozempic’s is semaglutide. Lilly markets tirzepatide for diabetes as Mounjaro and for weight loss as Zepbound.
Similarly, Novo markets semaglutide for diabetes as Ozempic and for weight loss as Wegovy.
Both tirzepatide and semaglutide belong to a class of drugs known as GLP-1s.